Better Times Ahead For Seres Therapeutics Inc (NASDAQ: MCRB)?

Seres Therapeutics Inc (MCRB) concluded trading on Wednesday at a closing price of $0.73, with 6.07 million shares of worth about $4.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -66.25% during that period and on April 3, 2024 the price saw a loss of about -4.88%. Currently the company’s common shares owned by public are about 135.04M shares, out of which, 114.13M shares are available for trading.

Stock saw a price change of -3.51% in past 5 days and over the past one month there was a price change of -36.35%. Year-to-date (YTD), MCRB shares are showing a performance of -48.17% which decreased to -87.20% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.73 but also hit the highest price of $6.87 during that period. The average intraday trading volume for Seres Therapeutics Inc shares is 4.65 million. The stock is currently trading -12.37% below its 20-day simple moving average (SMA20), while that difference is down -27.75% for SMA50 and it goes to -67.63% lower than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Seres Therapeutics Inc (NASDAQ: MCRB) currently have 135.04M outstanding shares and institutions hold larger chunk of about 44.23% of that.

The stock has a current market capitalization of $109.57M and its 3Y-monthly beta is at 2.25. It has posted earnings per share of -$0.90 in the same period. It has Quick Ratio of 1.48. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MCRB, volatility over the week remained 5.92% while standing at 8.10% over the month.

Analysts are in expectations that Seres Therapeutics Inc (MCRB) stock would likely to be making an EPS of -$0.34 in the current quarter, while forecast for next quarter EPS is -$0.31 and it is -$0.8 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.43 which is -$0.26 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.57 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -20.06% while it is estimated to increase by 27.94% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on June 26, 2023 offering an Outperform rating for the stock and assigned a target price of $12 to it. Coverage by JP Morgan stated Seres Therapeutics Inc (MCRB) stock as a Neutral in their note to investors on April 21, 2023, suggesting a price target of $7 for the stock. On July 23, 2021, Goldman Downgrade their recommendations, while on May 18, 2021, Goldman Resumed their ratings for the stock with a price target of $24. Stock get a Buy rating from Chardan Capital Markets on March 05, 2021.

Most Popular

Related Posts